Nadine Beauger
Director/Board Member at Immune Biosolutions, Inc.
Profile
Nadine Beauger is currently the Director at Immune Biosolutions, Inc. and also holds a Director position at ExCellThera, Inc. Previously, she worked as the President & Co-Chief Executive Officer at Insitut de Recherche en Immunologie et en Cancérologie and as a Patent Consultant at Léger Robic Richard LLP.
Beauger completed her undergraduate degree at McGill University and holds graduate, MBA, and doctorate degrees from the University of Montréal.
Nadine Beauger active positions
| Companies | Position | Start |
|---|---|---|
Immune Biosolutions, Inc.
 Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | Director/Board Member | 2020-01-22 |
ExCellThera, Inc.
 ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | Director/Board Member | - |
Former positions of Nadine Beauger
| Companies | Position | End |
|---|---|---|
Insitut de Recherche en Immunologie et en Cancérologie
 Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada. | Chief Executive Officer | 2023-02-26 |
Léger Robic Richard LLP
 Léger Robic Richard LLP Miscellaneous Commercial ServicesCommercial Services Léger Robic Richard LLP is a private company based in Montréal, Canada. | Corporate Officer/Principal | - |
Training of Nadine Beauger
| McGill University | Undergraduate Degree |
| University of Montréal | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Léger Robic Richard LLP
Léger Robic Richard LLP Miscellaneous Commercial ServicesCommercial Services Léger Robic Richard LLP is a private company based in Montréal, Canada. | Commercial Services |
Insitut de Recherche en Immunologie et en Cancérologie
Insitut de Recherche en Immunologie et en Cancérologie Miscellaneous Commercial ServicesCommercial Services Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada. | Commercial Services |
Immune Biosolutions, Inc.
Immune Biosolutions, Inc. BiotechnologyHealth Technology Immune Biosolutions, Inc. develops polyclonal, recombinant chicken antibodies, diagnostic tools, nutraceuticals and antibody based drugs to explore and resolve health issues. The firm’s products include light speed, sunrise, sunshine-in-a-box, eclipse blocking reagents and aurora detection reagents. The company was founded by Frédéric Leduc, Simon Gaudreau and Jean-François Larrivée in 2012 and is headquartered in Sherbrooke, Canada. | Health Technology |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | Health Technology |
- Stock Market
- Insiders
- Nadine Beauger
